Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PL...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Maojin, Chen, Ruijia, Wu, Qingfeng, Zhu, Wei, He, Ying, Huang, Yufan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643856/
https://www.ncbi.nlm.nih.gov/pubmed/36386191
http://dx.doi.org/10.3389/fphar.2022.1019826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643856/
https://www.ncbi.nlm.nih.gov/pubmed/36386191
http://dx.doi.org/10.3389/fphar.2022.1019826

Ejemplares similares